Phase 3 WU-KONG28 trial met its primary endpoint, showing that once-daily oral sunvozertinib significantly improved ...
Sunvozertinib achieved a statistically significant, clinically meaningful PFS advantage over platinum-based chemotherapy by ...
Please provide your email address to receive an email when new articles are posted on . Researchers did not observe insertional mutagenesis of CAR-T products among patients who developed secondary ...
New treatments may stall lung cancer progression in patients with EGFR exon 20 insertion mutations. After spending a warm spring day in 2022 pulling weeds and planting perennials, Renata Muller, 66, ...
Transposon mutagenesis has emerged as a robust genome-wide approach for the identification of cancer driver genes. By harnessing the natural mobility of transposable elements, researchers can induce ...
In the 15 November EMBO Reports Klinakis et al. describe a method for insertional mutagenesis and gene tagging that uses transposon-mediated mutagenesis (TRAMM) (EMBO Reports 2000, 1:416-421). They ...
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone ...
WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central ...
TOKYO, PRINCETON, N.J. and CAMBRIDGE, Mass., Jan. 28, 2025 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results